Every year, more than 795,000 people have a stroke, with up to 166,000 people developing central poststroke pain (CPSP). However, there is not a single medication that is FDA approved to treat CPSP, and there are very few studies that evaluate pharmacologic options. Of the studies that do, even fewer have robust data, with many case reports and open-label trials. The aim of this session is to present the available evidence for the pharmacological treatment of CPSP, including efficacy, adverse effects, and doses and provide reference materials for future use. In addition, practical considerations relating to CPSP will be discussed, such as stroke related complications that can complicate its treatment.